Pierre Fabre: Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association's (EMA) Committee for Medicinal Products Human use (CHMP) for their combination drugs to treat adult patients with advanced non-small cell-lung cancer (NSCLC) with BRAFV600E mutation. The post Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation appeared first on Pharmafile.